

The Critical Role of Epithelial-Derived Act1 in IL-17- and IL-25-Mediated Pulmonary Inflammation¹

Shadi Swaidani,^{*‡} Katarzyna Bulek,^{*} Zizhen Kang,^{*} Caini Liu,^{*} Yi Lu,^{*} Weiguo Yin,^{*} Mark Aronica,[†] and Xiaoxia Li^{2*}

IL-25 initiates, promotes, and augments Th2 immune responses. In this study, we report that Act1, a key component in IL-17-mediated signaling, is an essential signaling molecule for IL-25 signaling. Although Act1-deficient mice showed reduced expression of KC (CXCL1) and neutrophil recruitment to the airway compared with wild-type mice in response to IL-17 stimulation, Act1 deficiency abolished IL-25-induced expression of IL-4, IL-5, IL-13, eotaxin-1 (CCL11), and pulmonary eosinophilia. Using a mouse model of allergic pulmonary inflammation, we observed diminished Th2 responses and lung inflammation in Act1-deficient mice compared with wild-type mice. Importantly, Act1 deficiency in epithelial cells reduced the phenotype of allergic pulmonary inflammation due to loss of IL-17-induced neutrophilia and IL-25-induced eosinophilia, respectively. These results demonstrate the essential role of epithelial-derived Act1 in allergic pulmonary inflammation through the distinct impact of the IL-17R-Act1 and IL-25R-Act1 axes. Such findings are crucial for the understanding of pathobiology of atopic diseases, including allergic asthma, which identifies Act1 as a potential therapeutic target. *The Journal of Immunology*, 2009, 182: 1631–1640.

Allergic asthma is a chronic inflammatory disorder of the lung with a prevailing CD4⁺ T cell infiltrate in the airways, leading to bronchial hyperreactivity; recruitment of neutrophils, eosinophils, mast cells, and lymphocytes; and hyperplasia of smooth muscle, often associated with elevated serum IgE concentrations (1–3). CD4⁺ Th cells are essential regulators in chronic allergic diseases. Upon activation, Th cells undergo differentiation into functionally distinct effector subsets (4–8). Th1 cells produce IFN- γ and regulate cellular immunity, whereas Th2 cells produce IL-4, IL-5, and IL-13 and mediate humoral immunity and allergic responses. It is well known that Ag-induced allergic airway inflammation is mediated, in part, by Th2 cells and their cytokines (IL-4, IL-5, and IL-13). A novel Th cell subset expressing IL-17 has also recently been shown to regulate tissue inflammatory responses, including allergic airway inflammation (9).

IL-17A, produced by Th17 cells, is the prototypic IL-17 family member, exerting its actions either as a homodimer or as a heterodimer with IL-17F (10–12). IL-17A causes accumulation of neutrophils in the bronchoalveolar of rats and mice *in vivo*. The main function of IL-17A is to coordinate local tissue inflammation via the up-regulation of proinflammatory and neutrophil-mobilizing cytokines and chemokines (including IL-6, G-CSF, TNF- α , IL-1, CXCL1 (KC), CCL2 (MCP-1), CXCL2

(MIP-2), CCL7 (MCP-3), and CCL20 (MIP-3A)), as well as matrix metalloproteases to allow activated T cells to penetrate extracellular matrix. IL-17A deficiency leads to diminished Ag-specific T cell-mediated immune responses, including allergen-induced pulmonary inflammation and airway hyperresponsiveness (13, 14). Elevated IL-17 concentrations were found in the lung and blood of allergic asthma patients and linked to severity of asthma.

Homology-based cloning has revealed five additional IL-17 family members, termed IL-17B to IL-17F. The most divergent known member of the IL-17 family is IL-17E (IL-25); it is expressed in mouse T lymphocytes of the CD4⁺ subset with a Th2 profile and human innate effector eosinophils and basophils (15, 16). IL-25 has been shown to play a critical role in the initiation and propagation of the Th2 immune response (16–19). Transgenic expression as well as rIL-25 has been shown to induce Th2 immunity and increase Th2 cytokines IL-4, IL-5, and IL-13, eosinophilia, and IgE (15, 20, 21). IL25^{-/-} mice demonstrate a delayed expulsion of helminth parasites, indicative of an impairment of Th2 response (22, 23). Furthermore, endogenous IL-25 has been shown to be critical in allergen-induced pulmonary inflammation in a mouse asthma model (19). Elevated IL-25 and IL-25R expression were detected in asthmatic lung tissues, linking their roles in allergic pulmonary inflammation (16). Although previous studies showed that the cell type responsible for production of Th2 cytokines following IL-25 exposure is of a nonlymphocyte, non-NK, and nongranulocyte lineage, the identity of the IL-25-responsive cell type(s) remains elusive (15).

IL-17A signals through a heteromeric receptor complex, consisting of IL-17R (IL-17RA) and IL-17RC, which are single-pass transmembrane proteins and ubiquitously expressed in various cell types, including epithelial cells, fibroblasts, and astrocytes (24, 25). IL-25 signals through IL-25R (IL-17RB, also known as IL-17RH1), which is expressed in human lung, kidney, pancreas, liver, brain, and intestine (26, 27). IL-17RA, IL-17RC, and IL-25R (IL-17RB) belong to a newly defined SEFIR protein family, due to a conserved sequence segment

^{*}Department of Immunology and [†]Department of Pathobiology, Cleveland Clinic Foundation, Cleveland, OH 44195; and [‡]Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195

Received for publication August 25, 2008. Accepted for publication November 17, 2008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹This work was supported by National Institutes of Health Research Grant R01AI065470.

²Address correspondence and reprint requests to Dr. Xiaoxia Li, Department of Immunology, Cleveland Clinic, Cleveland, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail address: lix@ccf.org

Table I. The specific primer sequences used in reaction

Gene	Primer 1	Primer 2
Mouse β -actin	5'-GGTCATCACTATTGGCAACG-3'	5'-ACGGATGTCAACGTCACACT-3'
Mouse IL-5	5'-CTCACCGAGCTCTGTTGACAAG-3'	5'-CCAATGCATAGCTGGTGATTTTAT-3'
Mouse IL-4	5'-CTCATGGAGCTGCAGAGACTCTT-3'	5'-CATTTCATGGTGCAGCTTATCGA-3'
Mouse IL-13	5'-TGACCAACATCTCCAATTGCA-3'	5'-TTGTTATAAAGTGGGCTACTTTCGATTT-3'
Mouse eotaxin-1	5'-CCCAACTCCCCTGCTGCTTA-3'	5'-AGATCTCTTTGCCCCACCTG-3'
Mouse KC (CXCL1)	5'-TAGGGTGAGGACATGTGTGG-3'	5'-AAATGTCCAAGGGAAGCGT-3'
Mouse IL-25R	5'-GACGCGAAGGGACAGTTG-3'	5'-CAGCAGCACCAGGAAGAGAG-3'
Mouse IL-17	5'-CTCCACC GCAATGAAGAC-3'	5'-CTTTCCTCCGCATTTGAC-3'
Mouse Act1	5'-GCTTTGGCAGACTCCTTCAG-3'	5'-GGTAACACGAGGAGGTGAGG-3'
Mouse IFN- γ	5'-TGATGGCCTGATTGTCTTTCAA-3'	5'-GGATATCTGGAGGAAGTGGCAA-3'
Mouse TARC	5'-CAGGAAGTTGGTGAGCTGGT-3'	5'-GGGTCTGCACAGATGAGCTT-3'
Mouse IL-4R	5'-AGGCCCCAGTACAGAATGTG-3'	5'-CCAACAAGTCGGAAAACAGG-3'
Mouse MCP-1	5'-GCTGGAGCATCCACGTGTT-3'	5'-ATCTTGCTGGTGAATGAGTAGCA-3'

called SEFIR in their cytoplasmic domain (28). We recently found that a novel signaling molecule, Act1, is a key component in IL-17A signaling (29). Act1 contains two TNFR-associated factor (TRAF)³ binding sites, a helix-loop-helix domain at the N terminus, and a SEFIR domain at the C terminus, and therefore, Act1 is a member of the SEFIR protein family. Although the Act1 gene (*Traf3ip2*) was first cloned as an NF- κ B activator, our later studies showed that Act1, recruited to CD40 and the TNF family member B cell-activating factor receptor in B cells through its interaction with TRAF3, negatively regulates B cell survival (30, 31). BALB/c Act1-deficient mice also develop Sjogren's disease in association with lupus nephritis due to the hyper B cell function (32). Distinct from these previous findings, we recently reported that upon IL-17 stimulation, Act1 is recruited to IL-17R through the SEFIR domain, followed by the recruitment of TAK1 and TRAF6, mediating NF- κ B activation. Our data demonstrate the essential function of Act1 for IL-17-dependent signaling and autoimmune inflammatory disease (29).

In this study, we report a novel function of Act1 in mediating IL-25 signaling and IL-25-dependent Th2 pulmonary responses. Using a mouse model of allergic pulmonary inflammation, we observed reduced Th2 responses and lung inflammation in C57BL/6 Act1-deficient mice compared with littermate control wild-type mice. Importantly, Act1 deficiency in epithelial cells reduced IL-17-induced pulmonary neutrophilia and IL-25-mediated eosinophilia in the airway, indicating the essential role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation.

Materials and Methods

Mice, cell culture, and biological reagents

Act1-deficient (*Traf3ip2*^{-/-}) C57BL/6 (B6) mice were generated, as described previously (31). Mice were maintained in a temperature-controlled (23°C) facility with a strict 12-h light-dark cycle, and were given free access to food and water. The experiments were performed with gender-matched mice aged 6–8 wk. All animal protocols were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic Foundation (fully accredited by International Association for Assessment and Accreditation of Laboratory Animal Care) (29). HeLa cells were maintained in DMEM, supplemented with 10% FBS (HyClone), penicillin G (100 μ g/ml), and streptomycin (100 μ g/ml). Anti-V5 and anti-Flag (M2) were from Sigma-Aldrich; anti-phospho-JNK and anti-phospho-ERK were from Cell Signaling Technology.

Transfection and coimmunoprecipitation

HeLa cells were transiently transfected with 5 μ g of each Flag-tagged mouse Act1 and V5-tagged mouse IL-25R using Fugene6 (Roche), according to the manufacturer's instruction. For coimmunoprecipitations, cells were harvested, washed once with cold PBS, and lysed in a Triton X-100-containing buffer (0.5% Triton X-100, 20 mM HEPES (pH 7.4), 150 mM NaCl, 12.5 mM β -glycerophosphate, 1.5 mM MgCl₂, 10 mM NaF, 2 mM DTT, 1 mM sodium orthovanadate, 2 mM EGTA, 20 μ M aprotinin, and 1 mM PMSF). Cell extracts were incubated with 1 μ g of Ab (anti-Flag (M2 or anti-V5) or normal IgG (negative control)) for 2 h, followed by incubation for 2 h with 30 μ l of protein A-Sepharose beads (prewashed and resuspended in lysis buffer at a 1:1 ratio). After incubations, the beads were washed four times with lysis buffer, separated by SDS-PAGE, and analyzed by immunoblotting.

Mouse model of allergic pulmonary inflammation

Mice were immunized with 100 μ l of i.p. injection containing 10 μ g of OVA (chicken OVA, grade V; Sigma-Aldrich) and 20 mg of aluminum hydroxide (Sigma-Aldrich). Sham immunization with i.p. injection of PBS and 20 mg of aluminum hydroxide was used as a negative control for immunization procedure. Wild-type and Act1-deficient mice on a C57BL/6 background were immunized by two i.p. injections on days 1 and 8.

Control mice (K18-Cre^{+/+}-*Traf3ip2*^{+/fllox}) and epithelial-specific Act1-deficient mice (K18-Cre^{+/+}-*Traf3ip2*^{-fllox}) on BALBc/J background were immunized by one i.p. injection on day 1. Mice were challenged on days 14–17 by exposure to ~40 min of 1% OVA aerosol diluted in PBS. This was accomplished by placing mice in a 30 \times 60-cm acrylic box ventilated by NOUVAG Ultrasonic 2000 nebulizer (NOUVAG USA). Mice were sacrificed and processed on day 18, 24 h after last aerosol challenge.

Intranasal instillation of IL-17 and IL-25

Mice were anesthetized with isoflurane. Carrier-free, murine rIL-17 or rIL-25 (R&D Systems) resuspended in sterile saline (0.9%) was instilled into nasal opening in 50- μ l aliquot per mouse.

Bronchoalveolar lavage (BAL) and tissue collection

Mice were sacrificed at the times indicated. A total of 0.7 ml of HL-1 medium (BioWhittaker) was used to obtain BAL fluid through trachea using a blunt needle and 1-ml syringe. Cytospin slide preparations were obtained using Shandon CytoSpin III Cyto centrifuge (Shandon/Thermo Scientific). Differential leukocyte counts were obtained on cytospin slide preparation after Diff Quik Giemsa stain. Lungs were collected and snap frozen immediately in liquid nitrogen container. Total RNA was obtained by using TRIzol (Invitrogen) and OMNI TH tissue homogenizer (Omni International). H&E staining was obtained on lung tissue after fixation in 10% neutral buffered formalin and paraffin embedding.

Primary tracheal epithelial cell culture

Mice were sacrificed, and tracheas were excised, placed in medium containing 0.15% pronase, and incubated overnight at 4°C. Tracheal epithelial cells were harvested from supernatant and plated on collagen-coated cell culture plates. Total RNA isolated using TRIzol.

³ Abbreviations used in this paper: TRAF, TNFR-associated factor; BAL, bronchoalveolar lavage.




FIGURE 1. Act1 interacts with IL-25R. *A*, Domain structure of Act1 and IL-25R. The C terminus of Act1 contains a SEFIR domain that is a conserved sequence segment in the cytoplasmic domain of IL-17R family members, including IL-25R. *B–D*, Interaction between Act1 and IL-25R. *B–D*, HeLa cells were transiently transfected with Flag-tagged mAct1 and V5-tagged mouse IL-25R (*B*); Flag-tagged mAct1 and V5-tagged TLR4 (*C*); and Flag-tagged MyD88 and V5-tagged IL-25R (*D*). The lysates of transfected cells were immunoprecipitated (IP) with anti-Flag (M2) or anti-V5 Abs or IgG (control), followed by Western analysis (IB) with anti-M2 and anti-V5 Abs. Western blot analysis (IB) of whole-cell lysates for Act1 and IL-25R expression by anti-M2 and anti-V5 Abs. *E*, HeLa cells were transiently transfected with V5-tagged mouse IL-25R. The cells were treated with IL-25 (50 ng/ml) for 0, 5, 10, and 30 min, respectively. The lysates of untransfected (un) and transfected cells were immunoprecipitated (IP) with anti-V5, followed by Western analysis (IB) with anti-Act1 and anti-V5 Abs. Western blot analysis (IB) of whole-cell lysates for Act1 and IL-25R expression by anti-Act1 and anti-V5 Abs. The intensity of the immunoprecipitated Act1 bands was analyzed by Scion Image 1.62C alias and presented as percentage of the immunoprecipitated IL-25R bands (Ratio). *F* and *G*, HeLa cells were transiently transfected with Flag-tagged mAct1 or Act1 SEF deletion mutant (Δ SEF) and V5-tagged mouse IL-25R (*F*); Flag-tagged mAct1 and V5-tagged mouse IL-25R or IL-25R SEF deletion mutant (Δ SEF) (*G*). The lysates of transfected cells were immunoprecipitated (IP) with anti-V5, followed by Western analysis (IB) with anti-M2 and anti-V5 Abs. Western blot analysis (IB) of whole-cell lysates for mAct1 and IL-25R expression by anti-M2 and anti-V5 Abs.

OVA-specific Ig ELISA

OVA-specific Abs were determined using ELISA. Briefly, 96-well, flat-bottom protein absorbent polystyrene plates were coated with OVA (grade V; Sigma-Aldrich) at 10 μ g/well. Plates were then blocked with 2% FBS/PBS. Plates were washed with PBS. Serum samples and standards (OVA-specific IgG2a and IgE) were incubated at 4°C overnight. Biotinylated anti-mouse IgG2a or IgE was used, followed by streptavidin-conjugated

HRP. Plates were developed using ABTS-containing solution and quantified using Molecular Devices plate reader. Data were analyzed using Softmax pro v.5 software.

Statistical analysis

The data are presented as the mean \pm SEM with $n = 4$ animals per condition. The significance of differences between two groups was determined

by Student's *t* test (two-tailed). Statistical significance was reported if $p < 0.05$ was achieved.

Quantitative real-time PCR

A quantity amounting to 3 μg of total RNA was then used for the reverse-transcription reaction using Super Script II-reverse transcriptase (Invitrogen). Quantitative real-time PCR was performed in AB 7300 RealTime PCR System, and the gene expression was examined by SYBR Green PCR Master Mix (Applied Biosystems). PCR amplification was performed in triplicate, and water was used to replace cDNA in each run as a negative control. The reaction protocol included preincubation at 95°C to activate FastStart DNA polymerase for 10 min, amplification of 40 cycles that was set for 15 s at 95°C, and the annealing for 60 s at 60°C. The results were normalized with the housekeeping gene mouse β -actin. The specific primer sequences used in reaction are listed in Table I.

Results

Act1 is recruited to IL-25R through the SEFIR domain

Although IL-25 is the most divergent known member of the IL-17 family (also referred to as IL-17E), sequence analysis has shown that IL-25R also belongs to the defined SEFIR protein family, due to a conserved sequence segment called SEFIR in its cytoplasmic domain (Fig. 1A). We have previously reported that the adaptor molecule Act1 contains a SEFIR domain at its C-terminal region, through which Act1 is recruited to IL-17R (29). To investigate the possibility that Act1 also functions as an adaptor molecule for IL-25R, we coexpressed Flag-tagged Act1 and V5-tagged IL-25R in HeLa cells. Cell lysates from these transfected cells were immunoprecipitated with anti-Flag (M2) or anti-V5, followed by Western analyses with anti-Flag and anti-V5. As shown in Fig. 1, B–D, the coimmunoprecipitation experiments indicate that Act1 forms a complex with IL-25R, implicating the possible role of Act1 as an adaptor for IL-25R. IL-25 stimulation enhanced the interaction between Act1 and IL-25R (Fig. 1E). Transfection of the same expression construct of IL-25R into mouse embryonic fibroblasts rendered them responsive to IL-25 (induction of G-CSF), indicating that the epitope tag on the IL-25R does not interfere with signaling (data not shown). It is important to note that the interaction between Act1 and IL-25R was abolished when the SEFIR domain was deleted either from Act1 or from IL-25R, indicating the recruitment of Act1 to IL-25R is through the dimerization of the SEFIR domain (Fig. 1, F and G).

Act1 is required for IL-25-induced pulmonary eosinophilia and Th2 immune response

Previous studies have shown that IL-25 and IL-25R play an important role in mediating the initiation and propagation of the Th2 immune response, eosinophilia, and allergic lung inflammation. Intranasal injection of rIL-25 was able to induce a Th2 response in the airway manifested by an increase in Th2 cytokines, IL-4, IL-5, and IL-13, and marked eosinophilia. To examine the role of Act1 in IL-25R signaling in vivo, wild-type and Act1-deficient mice on a C57BL/6 background were treated with rIL-25 through intranasal injection. As shown in Fig. 2A, the eosinophils in the BAL were significantly reduced in Act1-deficient mice compared with that seen in wild-type mice 24 h after IL-25 stimulation. The expression of IL-25-induced Th2-associated genes was abolished or greatly reduced in Act1-deficient lung tissue, including cytokines IL-4, IL-5, and IL-13, and chemokine eotaxin (a potent eosinophil chemokine) (Fig. 2B). Taken together, these results demonstrate a previously unreported requirement of Act1 in mediating IL-25-induced eosinophilia and Th2 immune response. It is important to point out that IL-25-induced pulmonary responses (after 24 h of in-

tranasal IL-25 delivery) were not reduced in IL-17-deficient mice, suggesting that the observed IL-25 unresponsiveness in Act1-deficient mice was probably not due to the lack of IL-17 signaling.

Act1 is required for IL-17-induced pulmonary neutrophilia

The main function of IL-17A is to coordinate local tissue inflammation via the up-regulation of proinflammatory and neutrophil-mobilizing cytokines and chemokines. We have recently reported that Act1 is a key component in IL-17A signaling and required for IL-17-mediated inflammatory responses. To examine the impact of Act1 deficiency on IL-17-induced pulmonary inflammation, wild-type and Act1-deficient mice on a C57BL/6 background were treated with rIL-17 through intranasal injection. IL-17-induced neutrophil recruitment was significantly reduced in Act1-deficient mice compared with that in wild-type mice (Fig. 2C and supplementary Fig. 1).⁴ It is important to note that IL-17 stimulation does not lead to eosinophilia in the wild-type or Act1-deficient mice, which is consistent with the fact that IL-17 is a strong inducer of neutrophilia, but not eosinophilia. Th2-associated genes were not induced by IL-17 intranasal injection (data not shown). Instead, IL-17-induced expression of KC (CXCL1) (a potent neutrophil chemokine) and cytokine IL-6 was abolished in the lung of Act1-deficient mice compared with that in wild-type mice (Fig. 2D). Taken together, these results indicate that whereas Act1 plays an important role in IL-25-induced pulmonary eosinophilia, Act1 is required for IL-17-mediated neutrophilia in the airway.

Epithelial-derived Act1 is required for IL-17- and IL-25-mediated pulmonary inflammation

Although previous studies have shown that the cell type responsible for production of Th2 cytokines following IL-25 exposure is of a nonlymphocyte, non-NK, and nongranulocyte lineage, the identity of the IL-25-responsive cell type(s) in the airway remains to be elusive (15). In contrast, IL-17-mediated signaling has been implicated in the up-regulation of cytokines and chemokines in airway epithelial cells. Because Act1 is highly expressed in epithelial cells, including airway epithelial cells (33), we decided to determine the contribution of IL-17 and IL-25 signaling for the function of epithelial-derived Act1 in lung inflammation (34).

We have previously generated epithelial cell-specific Act1-deficient mice (29). Act1-deficient (*Traf3ip2*^{-/-}) mice were first bred onto K18-Cre transgenic mice (K18-Cre^{+/+}) to generate K18-Cre^{+/-}*Traf3ip2*^{+/-} mice (35). These mice were further bred onto Act1 floxed mice (*Traf3ip2*^{fl/fl}) to generate the control mice (K18-Cre^{+/-}*Traf3ip2*^{+/-fl/fl}) and epithelial-specific Act1-deficient mice (K18-Cre^{+/-}*Traf3ip2*^{-fl/fl}). Although Act1 expression was greatly reduced in colon epithelial cells from epithelial-specific Act1-deficient mice (K18-Cre^{+/-}*Traf3ip2*^{-fl/fl}) (29), Act1 expression was also abolished in airway epithelial cells from these epithelial-specific Act1-deficient mice (Fig. 3A). Control mice (K18-Cre^{+/-}*Traf3ip2*^{+/-fl/fl}) and epithelial-specific Act1-deficient mice (K18-Cre^{+/-}*Traf3ip2*^{-fl/fl}) were treated with rIL-25 or rIL-17 through intranasal injection. Importantly, IL-25-induced eosinophilia was significantly reduced in epithelial-specific Act1-deficient mice (K18-Cre^{+/-}*Traf3ip2*^{-fl/fl}) (Fig. 3B). Consistent with this, IL-25 induced low levels of Th2-associated gene expression in epithelial-specific Act1-deficient mice (K18-Cre^{+/-}*Traf3ip2*^{-fl/fl}) lung tissue, including cytokines IL-5, IL-13, and IL-4, and chemokine eotaxin (Fig. 3C). In contrast, IL-17-induced BAL cellularity and

⁴ The online version of this article contains supplementary material.




FIGURE 2. Act1 is required for IL-25- and IL-17-induced responses. Wild-type and Act1-deficient female mice on C57BL/6 background received intranasal administration of saline or rIL-25 (5 μ g/mouse) or rIL-17 (5 μ g/mouse) and were sacrificed and analyzed 24 h later. **A**, Reduced eosinophil accumulation in BAL from Act1-deficient mice compared with wild-type after IL-25 intranasal administration. **B**, Pulmonary expression (relative to wild-type saline-treated mice) of IL-25-associated genes (IL-5, eotaxin (CCL11), IL-13, and IL-4) in addition to IL-25R, KC (CXCL1), and IL-4R from real-time PCR analysis of total mRNA from lung tissue. **C**, Reduced neutrophil accumulation in BAL from Act1-deficient mice compared with wild-type after IL-17 intranasal administration. **D**, Pulmonary expression (relative to wild-type saline-treated mice) of IL-17-induced genes (KC (CXCL1) and IL-6) from real-time PCR analysis of total mRNA from lung tissue. Data represent means ($n = 4$) \pm SEM; p value indicated. The experiment was repeated three times.

neutrophil recruitment were also significantly diminished in epithelial-specific Act1-deficient mice (K18-Cre^{+/+}-*Traf3ip2*^{-flox}) compared with that in wild-type mice (Fig. 3, *D* and *E*). Taken together, these results indicate that epithelial-derived Act1 plays an important role in IL-25-induced eosinophilia and IL-17-mediated neutrophilia during lung inflammation.

Act1 is required for allergen-induced pulmonary inflammation

It is well known that Ag-induced allergic pulmonary inflammation is associated with Th2 immune response. Because Act1 is a key signaling component for both IL-25-mediated Th2 immune response and IL-17-induced inflammatory response, it is important to investigate the role of Act1 in allergic pulmonary inflammation. We examined the impact of Act1 deficiency on allergen-induced pulmonary inflammation using an OVA-induced model of allergic pulmonary inflammation. Although Act1-deficient mice on BALB/c background display B cell-mediated autoimmune phenotypes as early as 3 wk old (31), Act1-deficient mice in C57BL/6 background have a delayed onset of this phenotype (older than 6 mo) and a reduced onset of B cell-mediated autoimmune phenotypes. We therefore used fe-

male C57BL/6 Act1-deficient mice ($n = 5$) or wild-type littermates ($n = 5$) bred six generations for the allergen-induced pulmonary inflammation model. OVA/Alum-sensitized wild-type and Act1-deficient mice on a C57BL/6 background were challenged with OVA aerosol or saline, as described in *Materials and Methods*. Twenty-four hours after the last challenge, the mice were analyzed for BAL cells and lung inflammation. Lung and airway recruitment of granulocytes, predominantly eosinophils, were reduced in Act1-deficient mice compared with wild-type mice (Fig. 4, *A* and *B*). The eosinophils, macrophages, and lymphocytes in the BAL were also decreased in Act1-deficient mice (Fig. 4*C*). The low grade of pulmonary inflammation in the Act1-deficient mice correlates with decreased expression of chemokines (including eotaxin (eosinophil recruitment), thymus- and activation-regulated chemokine (CCL17), MCP1 (recruitment of macrophages), and KC (recruitment of neutrophils)) and Th2 cytokines (IL-5 and IL-13) in the lung tissues (Fig. 3*D* and supplementary Fig. 2).⁴ The induction of pulmonary eosinophilia in the mouse model of asthma requires the induction of both cellular as well as humoral immunity. Therefore, we also examined the induction




FIGURE 3. Epithelial-specific Act1 deficiency results in reduced IL-25- and IL-17-mediated pulmonary inflammation. *A*, Act1 expression from real-time PCR analysis of total mRNA of tracheal epithelial cells isolated from control mice (K18-Cre^{+/+}-Traf3ip2^{+/flox}) and epithelial-specific Act1-deficient mice (K18-Cre^{+/+}-Traf3ip2^{-flox}). Intranasal administration of rIL-25 (5 μ g/mouse; *B* and *C*) or rIL-17 (5 μ g/mouse; *D* and *E*) mice was sacrificed and analyzed 24 h later. *B*, Reduced IL-25-induced eosinophil accumulation in BAL from epithelial-specific Act1-deficient mice compared with wild type. *C*, IL-25-induced pulmonary expression (relative to wild-type saline-treated mice) of Th2-associated genes (IL-5, eotaxin (CCL11), IL-4, and IL-13) in addition to IL-4R and IL-25R from real-time PCR analysis of total mRNA from lung tissue. *D*, Reduced IL-17-induced neutrophil accumulation in BAL from epithelial-specific Act1-deficient mice compared with wild type. *E*, BAL cytopsin preparations stained with Wright-Giemsa, demonstrating reduced IL-17-induced airway inflammatory cell recovery in epithelial-specific Act1-deficient mice compared with wild type. Data represent means ($n = 4$) \pm SEM; p value indicated. The experiment was repeated three times.

of OVA-specific Ab production in wild-type and Act1-deficient animals after OVA sensitization. Interestingly, wild-type and Act1-deficient mice demonstrated equivalent induction of OVA-specific IgE and IgG2a (Fig. 4E).

Act1 deficiency in epithelial cells reduced allergen-induced pulmonary inflammation

As shown above, epithelial-derived Act1 plays an important role in IL-25-induced eosinophilia and IL-17-mediated neutrophilia during lung inflammation. Thus, we examined the impact of epithelial-specific Act1 deficiency in allergen-induced pulmonary inflammation. Importantly, we found that the allergen-induced pulmonary inflammation is reduced in the epithelial-

specific Act1-deficient mice (K18-Cre^{+/+}-Traf3ip2^{-flox}). Histologic analysis showed that Act1 deficiency in epithelial cells leads to reduced lung inflammation (Fig. 5A). The total number of BAL cells (including lymphocytes and eosinophils) was reduced in the epithelial-specific Act1-deficient mice (K18-Cre^{+/+}-Traf3ip2^{-flox}) (Fig. 5B). The reduced pulmonary inflammation in the epithelial-specific Act1-deficient mice correlates with decreased expression of some of Th2-associated genes, especially cytokine IL-13 in the lung tissues (Fig. 5C), although epithelial-specific Act1 deficiency had less impact on gene expression than complete Act1 deficiency. We also examined the induction of OVA-specific Ab production in wild-type and epithelial-specific Act1-deficient mice (K18-Cre^{+/+}-Traf3ip2^{-flox})





FIGURE 4. Reduced allergen-mediated pulmonary inflammatory responses in Act1-deficient mice. Wild-type and Act1-deficient female mice on C57BL/6 background were subjected to mouse model of allergen-mediated pulmonary inflammation, as described in *Materials and Methods*. *A*, H&E staining of lung tissue, demonstrating reduced lung inflammation in Act1-deficient mice compared with wild type. BAL cytopsin preparations stained with Wright-Giemsa, demonstrating reduced airway inflammatory cell recovery in Act1-deficient mice compared with wild type. *B*, Immunofluorescence staining of lung sections using anti-mouse major basic protein goat Ab (red) indicative of reduced eosinophil infiltration in Act1-deficient mice compared with wild type. *C*, Differential count analysis of BAL leukocytes, demonstrating reduced eosinophils, as well as macrophages and lymphocytes in Act1-deficient mice compared with wild type. *D*, Reduced pulmonary expression (relative to OVA/Alum-immunized wild-type mice following saline aerosol challenge) of Th2-associated genes (IL-4, IL-5, IL-13, eotaxin (CCL11), and IL-4R) and from real-time PCR analysis of total mRNA from lung tissue. *E*, Equivalent OVA-specific IgE and IgG2a induction following OVA/Alum sensitization ($n = 3$, repeated twice). Data represent means ($n = 5$, unless indicated otherwise) \pm SEM; p value indicated. The experiment was repeated three times.

after OVA sensitization. Interestingly, wild-type and epithelial-specific Act1-deficient mice (K18-Cre^{+/−}Traf3ip2^{−fllox}) demonstrated similar levels of OVA-specific IgE and IgG2a (Fig. 5D).

Discussion

Although IL-25 is an important regulator for the induction of Th2 immunity, the detailed molecular mechanism by which IL-25 signals is not yet clear. In this study, we show that Act1, a key component in IL-17-mediated signaling, is also an essential signaling molecule for IL-25 signaling. We previously reported that adaptor molecule Act1 contains a SEFIR domain at

its C-terminal region, through which Act1 is recruited to IL-17R (IL-17RA). Although IL-25 is the most divergent known member of the IL-17 family (also referred as IL-17E), sequence analysis showed that IL-25R also belongs to the SEFIR protein family. Coimmunoprecipitation experiments indicate that Act1 forms a complex with IL-25R (IL-17RB), confirming the role of Act1 as an adaptor for IL-25R (IL-17RB). It is important to note that a recent study by Rickel et al. (36) demonstrated an essential role for IL-17RA in IL-25 (IL-17E) signaling through the IL-25R (IL-17RB), suggesting the possibility for heterodimerization of IL-17RA and IL-17RB in mediating IL-25 (IL-17E)



signaling. Although the SEFIR domain of IL-17RA is required for its interaction with Act1 (29), we now found that the SEFIR domain of IL-17RB is also required for the recruitment of Act1 to the IL-25R (IL-17RB), suggesting the importance of both IL-17RA and IL-17RB in signaling.

It is important to note that IL-25 signaling is significantly distinct from IL-17 signaling in that it induces different biological responses linked to specific pathologies of various inflammatory diseases. Using IL-17-deficient mice, we have now confirmed that IL-25-induced pulmonary responses are independent of IL-17.

Therefore, the discovery of a common adaptor (Act1) downstream of IL-17R and IL-25R provides an opportunity to investigate specific aspects of IL-17- and IL-25-mediated signaling during inflammatory responses. It is important to note that both IL-17 and IL-25 signaling participate in Ag-induced allergic airway inflammation. In particular, the role of IL-25 has been reported to be crucial in the initiation and propagation of Ag-induced allergic inflammation. Ballantyne et al. (19) recently reported that blocking IL-25 signaling (IL-25 neutralizing Abs) reduced allergic pulmonary inflammatory responses in OVA-induced asthma model. We demonstrate the requirement for Act1 in the Th2-associated responses in mouse model of allergic pulmonary inflammation. Although Act1 plays an important role in IL-25-induced expression of Th2-associated genes (including IL-5, IL-13, and eotaxin-1), and pulmonary eosinophilia, Act1 is required for IL-17-mediated KC expression and neutrophilia in the airway. These results demonstrate the essential role of Act1 in allergic pulmonary inflammation through the differential impact of the IL-17R-Act1 and IL-25R-Act1 axes. Future studies are required to distinguish the relative contribution of IL-17-Act1 vs IL-25-Act1 axis in Ag-induced allergic pulmonary inflammation.

Both IL-17 and IL-25 signaling participate in Ag-induced allergic airway inflammation. One important task is to identify the cell types in which Act1 functions to mediate IL-17 and IL-25 signaling, contributing to allergic pulmonary inflammation. Intriguingly, Act1 deficiency in epithelial cells reduced the phenotype of allergic pulmonary inflammation. IL-17-induced BAL cellularity and lung inflammation were significantly reduced in epithelial-specific Act1-deficient mice compared with that in wild-type mice. In support of this, IL-17-induced Act1-mediated signaling has also been shown to enhance cytokine expression in human airway epithelial cells (37). These findings are consistent with our previous report that epithelial-specific Act1-deficient mice had reduced colitis due to reduced IL-17-dependent induction of chemokines that recruit neutrophils to the gut in a murine model of dextran sulfate sodium-induced colitis.

Previous studies have clearly shown that IL-25 plays important roles in promoting Th2 cell-mediated inflammation characterized by the infiltration of eosinophils. Recent studies in murine models suggest that IL-25 produced by lung epithelial cells may promote Th2 cell differentiation (17). To determine whether Act1 deficiency has any impact on the activation of OVA-specific T cells, we examined responses of Act1-deficient and wild-type splenocytes 15 days after immunization. Splenocytes from wild-type and Act1-deficient mice showed similar frequencies of T cells secreting IL-5 (data not shown). Therefore, it is clear that the activation of IL-5-producing Th2 cells was not inhibited in Act1-deficient mice, suggesting that the reduced pulmonary inflammation in Act1-deficient cells is not due to lack of Th2 cell differentiation. Previous studies have shown that the cell type responsible for production of Th2 cytokines following IL-25 exposure is of a non-lymphocyte, non-NK, and nongranulocyte lineage (15). Intriguingly, IL-25-induced eosinophilia was significantly reduced in epithelial-specific Act1-deficient mice. These results indicate a definitive role of epithelial-derived Act1 in IL-25-mediated Th2 immune response in vivo.

In summary, we found that Act1 deficiency in epithelial cells abolished IL-17-induced neutrophilia and IL-25-induced eosinophilia, leading to reduced allergic pulmonary inflammation. These results demonstrate the essential role of epithelial-derived Act1 in allergic pulmonary inflammation through the IL-17R-Act1 and IL-25R-Act1 axes. Further mechanistic study of IL-17R-Act1 vs IL-25R-Act1 signaling is crucial for our understanding of pathobiology of atopic diseases, including allergic asthma and atopic

dermatitis, which will facilitate pursuing Act1 as a potential therapeutic target.

Disclosures

The authors have no financial conflict of interest.

References

- Herrick, C. A., and K. Bottomly. 2003. To respond or not to respond: T cells in allergic asthma. *Nat. Rev. Immunol.* 3: 405–412.
- Wills-Karp, M. 1999. Immunologic basis of antigen-induced airway hyperresponsiveness. *Annu. Rev. Immunol.* 17: 255–281.
- Kay, A. B., S. Phipps, and D. S. Robinson. 2004. A role for eosinophils in airway remodelling in asthma. *Trends Immunol.* 25: 477–482.
- Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. *Immunity* 21: 467–476.
- Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity* 24: 179–189.
- Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor- β induces development of the TH17 lineage. *Nature* 441: 231–234.
- Harrington, L. E., R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy, K. M. Murphy, and C. T. Weaver. 2005. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat. Immunol.* 6: 1123–1132.
- Betelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature* 441: 235–238.
- Schnyder-Candrian, S., D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. Fossiez, B. Ryffel, and B. Schnyder. 2006. Interleukin-17 is a negative regulator of established allergic asthma. *J. Exp. Med.* 203: 2715–2725.
- Kawaguchi, M., L. F. Onuchic, X. D. Li, D. M. Essayan, J. Schroeder, H. Q. Xiao, M. C. Liu, G. Krishnaswamy, G. Germino, and S. K. Huang. 2001. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. *J. Immunol.* 167: 4430–4435.
- Wright J. F., F. Bennett, B. Li, J. Brooks, D. P. Luxenberg, M. J. Whitters, K. N. Tomkinson, L. J. Fitz, N. M. Wolfman, M. Collins, K. Dunussi-Joannopoulos, M. Chatterjee-Kishore, and B. M. Carreno. 2008. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. *J. Immunol.* 181: 2799–2805.
- Yang, X. O., S. H. Chang, H. Park, R. Nurieva, B. Shah, L. Acero, Y. H. Wang, K. S. Schluns, R. R. Broaddus, Z. Zhu, and C. Dong. 2008. Regulation of inflammatory responses by IL-17F. *J. Exp. Med.* 205: 1063–1075.
- Iwakura, Y., and H. Ishigame. 2006. The IL-23/IL-17 axis in inflammation. *J. Clin. Invest.* 116: 1218–1222.
- Nakae, S., Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. *Immunity* 17: 375–387.
- Hurst, S. D., T. Muchamuel, D. M. Gorman, J. M. Gilbert, T. Clifford, S. Kwan, S. Menon, B. Seymour, C. Jackson, T. T. Kung, et al. 2002. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. *J. Immunol.* 169: 443–453.
- Wang, Y. H., P. Angkasekwinai, N. Lu, K. S. Voo, K. Arima, S. Hanabuchi, A. Hippe, C. J. Corrigan, C. Dong, B. Homey, et al. 2007. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. *J. Exp. Med.* 204: 1837–1847.
- Angkasekwinai, P., H. Park, Y. H. Wang, Y. H. Wang, S. H. Chang, D. B. Corry, Y. J. Liu, Z. Zhu, and C. Dong. 2007. Interleukin 25 promotes the initiation of proallergic type 2 responses. *J. Exp. Med.* 204: 1509–1517.
- Cheung, P. F., C. K. Wong, W. K. Ip, and C. W. Lam. 2006. IL-25 regulates the expression of adhesion molecules on eosinophils: mechanism of eosinophilia in allergic inflammation. *Allergy* 61: 878–885.
- Ballantyne, S. J., J. L. Barlow, H. E. Jolin, P. Nath, A. S. Williams, K. F. Chung, G. Sturton, S. H. Wong, and A. N. McKenzie. 2007. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. *J. Allergy Clin. Immunol.* 120: 1324–1331.
- Sharkhuu, T., K. I. Matthaedi, E. Forbes, S. Mahalingam, S. P. Hogan, P. M. Hansbro, and P. S. Foster. 2006. Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity. *Clin. Exp. Allergy* 36: 1575–1583.
- Tamachi, T., Y. Maezawa, K. Ikeda, S. Kagami, M. Hatano, Y. Seto, A. Suto, K. Suzuki, N. Watanabe, Y. Saito, et al. 2006. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. *J. Allergy Clin. Immunol.* 118: 606–614.
- Fallon, P. G., S. J. Ballantyne, N. E. Mangan, J. L. Barlow, A. Dasvarma, D. R. Hewett, A. McIlgorm, H. E. Jolin, and A. N. McKenzie. 2006. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. *J. Exp. Med.* 203: 1105–1116.
- Owyang, A. M., C. Zaph, E. H. Wilson, K. J. Guildt, T. McClanahan, H. R. Miller, D. J. Cua, M. Goldschmidt, C. A. Hunter, R. A. Kastelein, and D. Artis. 2006. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. *J. Exp. Med.* 203: 843–849.

24. Toy, D., D. Kugler, M. Wolfson, B. T. Vanden, J. Gurgel, J. Derry, J. Tocker, and J. Peschon. 2006. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. *J. Immunol.* 177: 36–39.
25. Trajkovic, V., S. Stosic-Grujicic, T. Samardzic, M. Markovic, D. Miljkovic, Z. Ramic, and S. M. Mostarica. 2001. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. *J. Neuroimmunol.* 119: 183–191.
26. Maezawa, Y., H. Nakajima, K. Suzuki, T. Tamachi, K. Ikeda, J. Inoue, Y. Saito, and I. Iwamoto. 2006. Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. *J. Immunol.* 176: 1013–1018.
27. Wong, C. K., P. F. Cheung, W. K. Ip, and C. W. Lam. 2005. Interleukin-25-induced chemokines and interleukin-6 release from eosinophils is mediated by p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and nuclear factor κ B. *Am. J. Respir. Cell Mol. Biol.* 33: 186–194.
28. Novatchkova, M., A. Leibbrandt, J. Werzowa, A. Neubuser, and F. Eisenhaber. 2003. The STIR-domain superfamily in signal transduction, development and immunity. *Trends Biochem. Sci.* 28: 226–229.
29. Qian, Y., C. Liu, J. Hartupée, C. Z. Altuntas, M. F. Gulen, D. Jane-Wit, J. Xiao, Y. Lu, N. Giltiay, J. Liu, et al. 2007. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. *Nat. Immunol.* 8: 247–256.
30. Li, X., M. Commane, H. Nie, X. Hua, M. Chatterjee-Kishore, D. Wald, M. Haag, and G. R. Stark. 2000. Act1, an NF- κ B-activating protein. *Proc. Natl. Acad. Sci. USA* 97: 10489–10493.
31. Qian, Y., J. Qin, G. Cui, M. Naramura, E. C. Snow, C. F. Ware, R. L. Fairchild, S. A. Omori, R. C. Rickert, M. Scott, et al. 2004. Act1, a negative regulator in. *Immunity* 21: 575–587.
32. Qian, Y., N. Giltiay, J. Xiao, Y. Wang, J. Tian, S. Han, M. Scott, R. Carter, T. N. Jorgensen, and X. Li. 2008. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. *Eur. J. Immunol.* 38: 2219–2228.
33. Zhao, Z., Y. Qian, D. Wald, Y. F. Xia, J. G. Geng, and X. Li. 2003. IFN regulatory factor-1 is required for the up-regulation of the CD40-NF- κ B activator 1 axis during airway inflammation. *J. Immunol.* 170: 5674–5680.
34. Inoue, D., M. Numasaki, M. Watanabe, H. Kubo, T. Sasaki, H. Yasuda, M. Yamaya, and H. Sasaki. 2006. IL-17A promotes the growth of airway epithelial cells through ERK-dependent signaling pathway. *Biochem. Biophys. Res. Commun.* 347: 852–858.
35. Wen, F., G. Cecena, V. Munoz-Ritchie, E. Fuchs, P. Chambon, and R. G. Oshima. 2003. Expression of conditional *cre* recombinase in epithelial tissues of transgenic mice. *Genesis* 35: 100–106.
36. Rickel, E. A., L. A. Siegel, B. R. Yoon, J. B. Rottman, D. G. Kugler, D. A. Swart, P. M. Anders, J. E. Tocker, M. R. Comeau, and A. L. Budelsky. 2008. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. *J. Immunol.* 181: 4299–4310.
37. Huang, F., C. Y. Kao, S. Wachi, P. Thai, J. Ryu, and R. Wu. 2007. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF- κ B activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. *J. Immunol.* 179: 6504–6513.